

Developments in Biologicals

ISSN 1424-6074

118 PDA/EMEA European Virus Safety Forum

Editor: J.S. Robertson, Potters Bar, Herts., U.K.
XII + 180 p., 30 fig., 33 tab., soft cover 2004. ISBN 3-8055-7873-3

Viral safety is a key issue for biological and biotechnological medicinal products. This first joint PDA/EMEA European Virus Safety Forum brought together an international panel of speakers from the industry, regulatory authorities and research to present and discuss the most up-to-date scientific knowledge and regulatory aspects in the areas of virus safety of recombinant proteins, monoclonal antibodies, plasma-derived medicinal products and advanced technology medicinal products.

The conference provided the opportunity to discuss new approaches in viral safety such as generic or matrix validation of virus removal and novel virus inactivation/removal technologies, and to clarify their benefits and applicability for specific product categories or technologies. This volume will further the discussion on virus safety, contribute to the development of new regulatory guidance and support harmonisation of the regulations in this field.

KARGER

Contents

Session I

Regulatory Requirements

Chairs: *J.H. Trouvin* (AFSSAPS)
 A. Farrugia, (TGA)

European Regulatory Guidance on Virus Safety of Recombinant Proteins, Monoclonal Antibodies and Plasma Derived Medicinal Products

P. Celis, G. Silvester

Viral Safety Evaluation of Plasma-Derived Therapeutic Products

M. Farshid

Current and Future Approaches to Ensure the Viral Safety of Biopharmaceuticals

K. Brorson, L. Norling, E. Hamilton, S. Lute, K. Lee, S. Curtis, Y. Xu

An Industry Perspective on Plasma-Derived Products

I. von Hoegen

Industry Perspective for Biotech Products

A. Möritz

Session II

Testing Source Material

Chairs: *P. Korhola* (NAM)
 G. Vicari

Developing New Infectivity Assays

D.N. Galbraith

Qualification of Virus/Cell Systems for their Intended Use

A. Gröner

West Nile Virus NAT Testing

J. Saldanha, C. Cameron

Variants of B19

K.E. Brown

Session III (1)

Virus Validation, Virus Assay and Standardisation

Chairs: *H. Willkommen* (Clearant)
 G. Rössling (Schering)

Quantitative NAT for Pathogen Inactivation Verification

K. McKenney, L. Gillmeister, K. Marlowe, D. Armistead, W. Burgess, W. Drohan

Use of Bacteriophages as Surrogates for Mammalian Viruses

M. McAlister, H. Aranha, R. Larson

Session III (2)

Virus Validation, Model Viruses

Chairs: *H. Willkommen* (Clearant)

G. Rössling (Schering)

West Nile Virus: Recent Experience with the Model Virus Approach

T.R. Kreil

Cell Culture-Based Assay of Parvovirus B19 and the Relevance of Animal Model Viruses

J. Blümel

Methods for Validation of Hepatitis B Virus Inactivation

W.H. Gerlich, D. Glebe

Session IV

Virus Inactivation/Removal Technologies: Application and Validation

Chairs: *J. Löwer (PEI)*

E.-G. Graf (Pall)

Robustness Studies on Virus Inactivation: Definition of Parameters and their Generic Use

H. Dichtelmüller

PDA Virus Filter Task Force Update

G. Sofer

Gamma Irradiation of Intravenous Immunoglobulin

W.N. Drohan, S.I. Miekka, Y.V. Griko, R.-Y. Forng, R.E. Stafford, C.R. Hill, D.M. Mann, W.H.

Burgess

UV-C Irradiation of Human Albumin Solution on Manufacturing Scale

A.J. MacLeod

Session V

Virus Safety Aspects of Advanced Technology Medicinal Products

Chairs: *J. Robertson (NIBSC)*

H. Willkommen (Clearant)

Virological Issues in the Use of Cell Therapies

P.D. Minor

Animal Virus Contaminants of Biotechnology Products

D. Onions

Transgenic Animals for the Production of Biological Medicines

P.D. Minor